<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b392d14a-0c07-47d7-bc25-c2ae3e3d1fbe"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS. <br/>
      <br/>AZITHROMYCIN tablets, for oral use <br/>Initial U.S. Approval: 1991</title>
   <effectiveTime value="20250305"/>
   <setId root="df5abe91-2866-4b1a-97f1-4c61fee8f01f"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="963322560" root="1.3.6.1.4.1.519.1"/>
            <name>TAGI Pharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="421303775" root="1.3.6.1.4.1.519.1"/>
                        <name>CSPC Ouyi Pharmaceutical Co., Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51224-222" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51224-222" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51224-222" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="06e87f0c-9279-4727-bfd0-4b91801f98d5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20211109"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51224-222" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Azithromycin dihydrate</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Azithromycin dihydrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="600" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5FD1131I7S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Azithromycin dihydrate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J2KLZ20U1M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Azithromycin anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O7TSZ97GEP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51224-222-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190701"/>
                                    <high value="20250930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207566" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20190701"/>
                              <high value="20250930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">OE;600</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="5885c98e-0781-48d4-a3cb-124fb3f8517e"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="85%" align="left" valign="top"/>
                           <col width="15%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Cardiovascular Death (<linkHtml href="#S5.5">5.5</linkHtml>)</td>
                                 <td>07/2021</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="4c908f10-8b4f-4575-b7e2-00547527d40e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.</paragraph>
               </text>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Mycobacterial Infections (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (<linkHtml href="#S1.3">1.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.2">
                     <id root="a1f420e1-590e-45ca-a347-5d52fd37a4ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Mycobacterial Infections</title>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="a3a6b04f-ade2-4f77-aea1-70a1379ee74d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Prophylaxis of Disseminated Mycobacterium avium complex (MAC) Disease </content>
                              </paragraph>
                              <paragraph>Azithromycin tablets, taken alone or in combination with rifabutin at its approved dose, are indicated for the prevention of disseminated MAC disease in persons with advanced HIV infection.  <content styleCode="italics"> [see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3b9ffe63-42f2-4631-a7d5-37e9360b860c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Treatment of Disseminated MAC Disease</content>
                              </paragraph>
                              <paragraph>Azithromycin tablets, taken in combination with ethambutol, are indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection<content styleCode="italics">.</content>
                                 <content styleCode="italics"> [see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml> and <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="cf7afb3d-ea90-4ca4-aec8-53ea6e04af24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs, azithromycin tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="649bc072-e006-4d27-978b-5def7db7d54f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>]</content>
                  </paragraph>
                  <paragraph>Azithromycin can be taken with or without food. However, increased tolerability has been observed when tablets are taken with food.</paragraph>
                  <paragraph>For pediatric suspension see the prescribing information for azithromycin for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles.</paragraph>
               </text>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Mycobacterial Infections (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.2">
                     <id root="c89f07b0-428b-4a38-bf0f-9be4ac3accf5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Mycobacterial Infections</title>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="ccc4b136-2c06-4d52-a6f3-cd1c4c0fab81"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Prevention of Disseminated MAC Infections</content>
                              </paragraph>
                              <paragraph>The recommended dose of azithromycin tablets for the prevention of disseminated <content styleCode="italics">Mycobacterium avium</content> complex (MAC) disease is: 1,200 mg taken once weekly. This dose of azithromycin tablets may be combined with the approved dosage regimen of rifabutin.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="54ad6e84-2a7a-4f84-b7e0-89fafb53b6d2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Treatment of Disseminated MAC Infections </content>
                              </paragraph>
                              <paragraph>Azithromycin should be taken at a daily dose of 600 mg, in combination with ethambutol at the recommended daily dose of 15 mg/kg. Other antimycobacterial drugs that have shown <content styleCode="italics">in vitro</content> activity against MAC may be added to the regimen of azithromycin plus ethambutol at the discretion of the physician or health care provider.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="75136811-ef7b-414c-8f0d-d6a9a4b966d1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Azithromycin Tablets USP, 600 mg (debossed "OE" on one side and "600" on the other side) are supplied as white, oval-shaped, film coated tablets containing azithromycin dihydrate equivalent to 600 mg azithromycin.</paragraph>
               </text>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Azithromycin Tablets, 600 mg (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="6441b3fe-d498-4929-aac7-532c3c2b8b5e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide antibiotic. (<linkHtml href="#S4.1">4.1</linkHtml>) </item>
                           <item>Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. (<linkHtml href="#S4.2">4.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.1">
                     <id root="d4c3a56d-9aa8-45e1-aea2-1d715a3dddb2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity</title>
                     <text>
                        <paragraph>Azithromycin tablets are contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide drug.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.2">
                     <id root="70df86fe-7593-4903-8196-73613401c737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Hepatic Dysfunction</title>
                     <text>
                        <paragraph>Azithromycin tablets are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="1edb7523-ff23-4dfe-b2f4-c84c4baec417"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Serious (including fatal) allergic and skin reactions. Discontinue azithromycin and initiate appropriate therapy if reaction occurs. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Hepatotoxicity: Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>Cardiovascular Death: Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. Consider balancing this potential risk with treatment benefits when prescribing azithromycin. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridium difficile</content>-Associated Diarrhea: Evaluate patients if diarrhea occurs. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>Azithromycin may exacerbate muscle weakness in persons with myasthenia gravis. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="016f59d8-ea41-4a8a-93a5-b8b5401afec8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity</title>
                     <text>
                        <paragraph>Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome, and toxic epidermal necrolysis, have been reported rarely in patients on azithromycin therapy. <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported. Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is presently unknown.</paragraph>
                        <paragraph>If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that allergic symptoms may reappear when symptomatic therapy is discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="d3cc426b-05d3-4226-bd5b-60eb5bba3d96"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hepatotoxicity</title>
                     <text>
                        <paragraph>Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="6186c90f-87f7-49de-b32f-f37f047da043"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS)</title>
                     <text>
                        <paragraph>Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="d2979730-3e70-465d-b7d9-d765c042a0c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 QT Prolongation</title>
                     <text>
                        <paragraph>Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen with treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure</item>
                           <item>patients on drugs known to prolong the QT interval</item>
                           <item>patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.</item>
                        </list>
                        <paragraph>Elderly patients may be more susceptible to drug-associated effects on the QT interval.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="e690a423-ff3b-43d0-80d5-b25c09927394"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Cardiovascular Death</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. The five-day cardiovascular mortality observed in these studies ranged from 20 to 400 per million azithromycin treatment courses. This potential risk was noted to be greater during the first five days of azithromycin use and does not appear to be limited to those patients with preexisting cardiovascular diseases. The data in these observational studies are insufficient to establish or exclude a causal relationship between acute cardiovascular death and azithromycin use. Consider balancing this potential risk with treatment benefits when prescribing azithromycin.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="83c2c04c-1259-4dc3-a34c-3779cb4eac91"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 <content styleCode="italics">Clostridium difficile</content>-Associated Diarrhea (CDAD)</title>
                     <text>
                        <paragraph>CDAD has been reported with use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin<content styleCode="bold">-</content>producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="c21aabda-8f4e-4210-8ada-a41b2abee857"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Exacerbation of Myasthenia Gravis</title>
                     <text>
                        <paragraph>Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="2c27cda3-abfd-4eab-833b-60bc134c447e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="9a5ee2b7-155e-4d54-b2d8-b679be6305c6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in labeling: </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hypersensitivity <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Infantile Hypertrophic Pyloric Stenosis (IHPS) <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>QT Prolongation <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Cardiovascular Death <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Clostridiodes difficile-Associated Diarrhea (CDAD) <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Exacerbation of Myasthenia Gravis <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions are diarrhea (5%), nausea (3%), abdominal pain (3%), or vomiting, (no percent given). (<linkHtml href="#S6">6</linkHtml>) </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact TAGI Pharma, Inc. at 1-855-225-8244 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="1545b345-1730-489e-99f5-e0f02b90e395"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In clinical trials, most of the reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug. Approximately 0.7% of the patients from the multiple-dose clinical trials discontinued azithromycin therapy because of treatment-related adverse reactions. Serious adverse reactions included angioedema and cholestatic jaundice. Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. <content styleCode="italics">[see Clinical Studies (14.2)]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="8ec71ea2-f16f-4d0b-a514-822018595f5d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Multiple-dose regimen</content>
                              </paragraph>
                              <paragraph>Overall, the most common adverse reactions in adult patients receiving a multiple-dose regimen of azithromycin were related to the gastrointestinal system with diarrhea/loose stools (5%), nausea (3%), and abdominal pain (3%) being the most frequently reported.</paragraph>
                              <paragraph>No other adverse reactions occurred in patients on the multiple-dose regimen of azithromycin with a frequency greater than 1%. Adverse reactions that occurred with a frequency of 1% or less included the following:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiovascular:</content> Palpitations and chest pain.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal:</content> Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Genitourinary:</content> Monilia, vaginitis, and nephritis.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous System:</content> Dizziness, headache, vertigo, and somnolence.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">General:</content> Fatigue.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Allergic:</content> Rash, photosensitivity, and angioedema.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="31893db1-9f18-4d9b-9987-78a75b611064"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Chronic therapy with 1,200 mg weekly regimen</content>
                              </paragraph>
                              <paragraph>The nature of adverse reactions seen with the 1200 mg weekly dosing regimen for the prevention of <content styleCode="italics">Mycobacterium avium</content> infection in severely immunocompromised HIV-infected patients were similar to those seen with short-term dosing regimens. <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="260853d7-5a67-43d5-8c13-7474890756fa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Chronic therapy with 600 mg daily regimen combined with ethambutol</content>
                              </paragraph>
                              <paragraph>The nature of adverse reactions seen with the 600 mg daily dosing regimen for the treatment of <content styleCode="italics">Mycobacterium avium</content> complex infection in severely immunocompromised HIV-infected patients were similar to those seen with short term dosing regimens. Five percent of patients experienced reversible hearing impairment in the pivotal clinical trial for the treatment of disseminated MAC in patients with AIDS. Hearing impairment has been reported with macrolide antibiotics, especially at higher doses. Other treatment-related adverse reactions occurring in &gt; 5% of subjects and seen at any time during a median of 87.5 days of therapy include: abdominal pain (14%), nausea (14%), vomiting (13%), diarrhea (12%), flatulence (5%), headache (5%), and abnormal vision (5%). Discontinuations from treatment due to laboratory abnormalities or adverse reactions considered related to study drug occurred in 8 of 88 (9.1%) of subjects.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="dfbcab38-e5cf-42fc-a115-1f3c0a22407a"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of azithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Adverse reactions reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a causal relationship may not be established include: </paragraph>
                        <paragraph>
                           <content styleCode="italics">Allergic:</content> Arthralgia, edema, urticaria, and angioedema. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular:</content> Arrhythmias including ventricular tachycardia and hypotension. There have been reports of QT prolongation and <content styleCode="italics">torsades de pointes</content>, and cardiovascular death.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea, pseudomembranous colitis, pancreatitis, oral candidiasis, pyloric stenosis, and tongue discoloration.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General:</content> Asthenia, paresthesia, fatigue, malaise, and anaphylaxis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Genitourinary:</content> Interstitial nephritis, acute renal failure, and vaginitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematopoietic:</content> Thrombocytopenia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Liver/Biliary:</content> Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure. <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System:</content> Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity, nervousness, agitation, and syncope.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric:</content> Aggressive reaction and anxiety.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin/Appendages:</content> Pruritus, and serious skin reactions including erythema multiforme, AGEP, Stevens-Johnson Syndrome, toxic epidermal necrolysis, and DRESS.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses:</content> Hearing disturbances including hearing loss, deafness, and/or tinnitus, and reports of taste/smell perversion and/or loss.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.3">
                     <id root="e6e38464-1f73-41a7-b3ac-27e035e0e0bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Laboratory Abnormalities </title>
                     <text>
                        <paragraph>Significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>With an incidence of 1% to 2%, elevated serum creatine phosphokinase, potassium, ALT (SGPT), GGT, and AST (SGOT). </item>
                           <item>With an incidence of less than 1%, leukopenia, neutropenia, decreased platelet count, elevated serum alkaline phosphatase, bilirubin, BUN, creatinine, blood glucose, LDH, and phosphate.</item>
                        </list>
                        <paragraph>When follow-up was provided, changes in laboratory tests appeared to be reversible.</paragraph>
                        <paragraph>In multiple-dose clinical trials involving more than 3,000 patients, 3 patients discontinued therapy because of treatment-related liver enzyme abnormalities and 1 because of a renal function abnormality. </paragraph>
                        <paragraph>In a phase 1 drug interaction study performed in normal volunteers, 1 of 6 subjects given the combination of azithromycin and rifabutin, 1 of 7 given rifabutin alone, and 0 of 6 given azithromycin alone developed a clinically significant neutropenia (&lt; 500 cells/mm<sup>3</sup>).</paragraph>
                        <paragraph>Laboratory abnormalities seen in clinical trials for the prevention of disseminated <content styleCode="italics">Mycobacterium avium</content> disease in severely immunocompromised HIV-infected patients. <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>Chronic therapy (median duration: 87.5 days, range: 1 to 229 days) that resulted in laboratory abnormalities in &gt; 5% of subjects with normal baseline values in the pivotal trial for treatment of disseminated MAC in severely immunocompromised HIV<content styleCode="bold">-</content>infected patients treated with azithromycin 600 mg daily in combination with ethambutol include: a reduction in absolute neutrophils to &lt; 50% of the lower limit of normal (10/52, 19%) and an increase to five times the upper limit of normal in alkaline phosphatase (3/35, 9%). These findings in subjects with normal baseline values are similar when compared to all subjects for analyses of neutrophil reductions (22/75, 29%) and elevated alkaline phosphatase (16/80, 20%). Causality of these laboratory abnormalities due to the use of study drug has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="1af20746-e2c3-4b2f-964d-855f284f9800"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Nelfinavir: Close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (<linkHtml href="#S7.1">7.1</linkHtml>) </item>
                           <item>Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. (<linkHtml href="#S7.2">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="609e4951-5e3d-49a7-a4e5-8135652cfe25"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Nelfinavir</title>
                     <text>
                        <paragraph>Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="8e5c7933-573c-44b3-9db5-fc3ff0a7546e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Warfarin</title>
                     <text>
                        <paragraph>Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants such as warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and warfarin. Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="1acf1324-9877-4c45-92d5-bfb043914077"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Potential Drug-Drug Interaction with Macrolides</title>
                     <text>
                        <paragraph>Interactions with digoxin, colchicine or phenytoin have not been reported in clinical trials with azithromycin. No specific drug interaction studies have been performed to evaluate potential drug-drug interaction. However, drug interactions have been observed with other macrolide products. Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="1368097c-3f82-438e-93ee-35b3e2308445"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Pediatric Use: Safety and effectiveness in the treatment of patients under 6 months of age have not been established. (<linkHtml href="#S8.4">8.4</linkHtml>)</item>
                           <item>Geriatric Use: Elderly patients may be more susceptible to development of torsades de pointes arrhythmias. (<linkHtml href="#S8.5">8.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="188dc39f-dee6-4a50-9b7e-feb7143fc894"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="baa5c8a4-d7e6-4811-9ade-21fc252a8434"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes <content styleCode="italics">(see <linkHtml href="#Data1">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced fetal malformations at doses up to 3, 2, and 1 times, respectively, an adult human daily dose of 600 mg based on body surface area. Decreased viability and delayed development were observed in the offspring of pregnant rats administered azithromycin from day 6 of pregnancy through weaning at a dose equivalent to 3 times an adult human daily dose of 600 mg based on body surface area <content styleCode="italics">(see <linkHtml href="#Data1">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data1">
                           <id root="9b25b7eb-c3b0-4cb0-8029-da50c01e531d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                           <component>
                              <section>
                                 <id root="a770b838-aee4-4958-b880-bfb2f9cfd62b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant women. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications.</paragraph>
                                 </text>
                                 <effectiveTime value="20211109"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="6b4c29d0-c6df-4e0b-820d-80badc158e16"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Azithromycin administered during the period of organogenesis did not cause fetal malformations in rats and mice at oral doses up to 200 mg/kg/day (moderately maternally toxic). Based on body surface area, this dose is approximately 3 (rats) and 2 (mice) times an adult human daily dose of 600 mg. In rabbits administered azithromycin at oral doses of 10 mg/kg/day, 20 mg/kg/day, and 40 mg/kg/day during organogenesis, reduced maternal body weight and food consumption were observed in all groups; no evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is approximately equal to an adult human daily dose of 600 mg based on body surface area.</paragraph>
                                    <paragraph>In a pre- and postnatal development study, azithromycin was administered orally to pregnant rats from day 6 of pregnancy until weaning at doses of 50 mg/kg/day or 200 mg/kg/day. Maternal toxicity (reduced food consumption and body weight gain; increased stress at parturition) was observed at the higher dose. Effects in the offspring were noted at 200 mg/kg/day during the postnatal development period (decreased viability, delayed developmental landmarks). These effects were not observed in a pre- and postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 of pregnancy until weaning.</paragraph>
                                 </text>
                                 <effectiveTime value="20211109"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="02067e83-3007-4874-a9ac-94410be8d315"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="71258e88-df2a-4034-88f2-36193afa1eb4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Azithromycin is present in human milk <content styleCode="italics">(see <linkHtml href="#Data2">Data</linkHtml>)</content>. Non-serious adverse reactions have been reported in breastfed infants after maternal administration of azithromycin <content styleCode="italics">(see <linkHtml href="#CC">Clinical Considerations</linkHtml>)</content>. There are no available data on the effects of azithromycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for azithromycin and any potential adverse effects on the breastfed infant from azithromycin or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="3b73ae38-aa4e-4236-98b0-952cc2963f49"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Advise women to monitor the breastfed infant for diarrhea, vomiting, or rash.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data2">
                           <id root="24d905e4-e2c1-4a90-abcd-c898e41b1e3f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Azithromycin breastmilk concentrations were measured in 20 women after receiving a single 2 g oral dose of azithromycin during labor. Breastmilk samples collected on days 3 and 6 postpartum as well as 2 and 4 weeks postpartum revealed the presence of azithromycin in breastmilk up to 4 weeks after dosing. In another study, a single dose of azithromycin 500 mg was administered intravenously to 8 women prior to incision for cesarean section. Breastmilk (colostrum) samples obtained between 12 and 48 hours after dosing revealed that azithromycin persisted in breastmilk up to 48 hours.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="82e0bebd-76af-4a25-93d2-60ddc7c90f90"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>In controlled clinical studies, azithromycin has been administered to pediatric patients ranging in age from 6 months to 12 years. For information regarding the use of azithromycin for oral suspension in the treatment of pediatric patients, <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml> and <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content> of the prescribing information for azithromycin for oral suspension 100 mg/ 5 mL and 200 mg/5 mL bottles.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="5f3d2c0c-fd1f-4982-9fd5-a8426430058a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">HIV-Infected Pediatric Patients:</content> The safety and efficacy of azithromycin for the prevention or treatment of MAC in HIV-infected children have not been established. Safety data are available for 72 children 5 months to 18 years of age (mean 7 years) who received azithromycin for treatment of opportunistic infections. The mean duration of therapy was 242 days (range 3 to 2,004 days) at doses of &lt; 1 mg/kg/day to 52 mg/kg/day (mean 12 mg/kg/day). Adverse reactions were similar to those observed in the adult population, most of which involved the gastrointestinal tract. Treatment<content styleCode="bold">-</content>related reversible hearing impairment in children was observed in 4 subjects (5.6%). Two (2.8%) children prematurely discontinued treatment due to adverse reactions: one due to back pain and one due to abdominal pain, hot and cold flushes, dizziness, headache, and numbness. A third child discontinued due to a laboratory abnormality (eosinophilia). The protocols upon which these data are based specified a daily dose of 10 mg/kg/day to 20 mg/kg/day (oral and/or IV) of azithromycin.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="b88d88a0-3a88-4ea0-92c1-a54e78390448"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age (458/4,949) and 3% of patients (144/4,949) were at least 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients. <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>Azithromycin 600 mg tablets contain 2.1 mg of sodium per tablet.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="8a91e57e-3baf-40aa-a0a8-49c514d4a750"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Geriatric Patients with Opportunistic Infections, Including (MAC) Disease:</content> Safety data are available for 30 patients (65 to 94 years old) treated with azithromycin at doses &gt; 300 mg/day for a mean of 207 days. These patients were treated for a variety of opportunistic infections, including MAC. The adverse reaction was generally similar to that seen in younger patients, except for a higher incidence of adverse reactions relating to the gastrointestinal system and to reversible impairment of hearing. <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="cc4898de-6181-4564-afd4-86c13bbbb790"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Adverse reactions experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required.</paragraph>
               </text>
               <effectiveTime value="20211109"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="ec4c7a80-09fd-4694-a16e-58f7476e67b0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Azithromycin tablets, USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (<content styleCode="italics">2R,3S,4R,5R,8R,10R,11R,12S,13S,14R</content>)-13-[(2,6-dideoxy-3-<content styleCode="italics">C</content>-methyl-3-<content styleCode="italics">O</content>-methyl--<content styleCode="italics">L</content>-<content styleCode="italics">ribo</content>-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)--<content styleCode="italics">D</content>-<content styleCode="italics">xylo</content>-hexopyranosyl] oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring. Its molecular formula is C<sub>38</sub>H<sub>72</sub>N<sub>2</sub>O<sub>12</sub>, and its molecular weight is 749.0. Azithromycin has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Azithromycin, as the dihydrate, is a white crystalline powder with a molecular formula of C<sub>38</sub>H<sub>72</sub>N<sub>2</sub>O<sub>12</sub>2H<sub>2</sub>O and a molecular weight of 785.0.</paragraph>
                  <paragraph>Azithromycin tablets, USP contain azithromycin dihydrate equivalent to 600 mg azithromycin. They also contain the following inactive ingredients: croscarmellose sodium, dibasic calcium phosphate anhydrous, magnesium stearate, pregelatinized starch, and an aqueous film coat of macrogol/PEG, polyvinyl alcohol, talc, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20211109"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="azithromycin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="78ffe512-1410-4d5d-b720-562a47844ff1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211109"/>
               <component>
                  <section ID="S12.1">
                     <id root="063fc8b2-ddeb-4a5d-b237-20af03feab92"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Azithromycin is a macrolide antibacterial drug. <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="b34164a3-455f-4b3e-b36d-7bb9693115b2"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for certain pathogens (<content styleCode="italics">S. pneumoniae</content> and <content styleCode="italics">S. aureus</content>).</paragraph>
                        <paragraph>The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with azithromycin.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="30f3dde7-67c6-483a-9bb5-c0fc8bf5fb0e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Cardiac Electrophysiology </content>
                              </paragraph>
                              <paragraph>QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1,000 mg) alone or in combination with oral azithromycin (500 mg, 1,000 mg, and 1,500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration-dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1,000 mg and 1,500 mg azithromycin, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="1f59730c-a0a3-4523-b7af-96a217276de1"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetic parameters of azithromycin in plasma after dosing as per labeled recommendations in healthy young adults and asymptomatic HIV-positive adults (age 18 to 40 years old) are portrayed in the following chart:</paragraph>
                        <table width="90%">
                           <caption>MEAN (CV%) PK PARAMETER</caption>
                           <col width="26%" align="left" valign="top"/>
                           <col width="9%" align="center" valign="middle"/>
                           <col width="9%" align="center" valign="middle"/>
                           <col width="10%" align="center" valign="middle"/>
                           <col width="8%" align="center" valign="middle"/>
                           <col width="10%" align="center" valign="middle"/>
                           <col width="10%" align="center" valign="middle"/>
                           <col width="8%" align="center" valign="middle"/>
                           <col width="10%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="middle">DOSE/DOSAGE FORM<br/> (serum, except as indicated)</th>
                                 <th styleCode="Rrule">Subjects</th>
                                 <th styleCode="Rrule">Day No.</th>
                                 <th styleCode="Rrule">C<sub>max</sub>
                                    <br/>(mcg/mL)</th>
                                 <th styleCode="Rrule">T<sub>max</sub>
                                    <br/>(hr)</th>
                                 <th styleCode="Rrule">C<sub>24</sub>
                                    <br/>(mcg/mL)</th>
                                 <th styleCode="Rrule">AUC<br/> (mcghr/mL)</th>
                                 <th styleCode="Rrule">T<br/>(hr)</th>
                                 <th styleCode="Rrule">Urinary Excretion<br/> (% of dose)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">500 mg/250 mg capsule</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">1</td>
                                 <td styleCode="Rrule">0.41</td>
                                 <td styleCode="Rrule">2.5</td>
                                 <td styleCode="Rrule">0.05</td>
                                 <td styleCode="Rrule">2.6<footnote ID="ft1">AUC<sub>0-24</sub>;</footnote>
                                 </td>
                                 <td styleCode="Rrule"></td>
                                 <td styleCode="Rrule">4.5</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">and 250 mg on Days 2 to 5</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">5</td>
                                 <td styleCode="Rrule">0.24</td>
                                 <td styleCode="Rrule">3.2</td>
                                 <td styleCode="Rrule">0.05</td>
                                 <td styleCode="Rrule">2.1<footnoteRef IDREF="ft1"/>
                                 </td>
                                 <td styleCode="Rrule"></td>
                                 <td styleCode="Rrule">6.5</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">1,200 mg/600 mg tablets</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">1</td>
                                 <td styleCode="Rrule">0.66</td>
                                 <td styleCode="Rrule">2.5</td>
                                 <td styleCode="Rrule">0.074</td>
                                 <td styleCode="Rrule">6.8<footnote>0-last.</footnote>
                                 </td>
                                 <td styleCode="Rrule">40</td>
                                 <td styleCode="Rrule"></td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">%CV</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">(62%)</td>
                                 <td styleCode="Rrule">(79%)</td>
                                 <td styleCode="Rrule">(49%)</td>
                                 <td styleCode="Rrule">(64%)</td>
                                 <td styleCode="Rrule">(33%)</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">600 mg tablet/day</td>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">1</td>
                                 <td styleCode="Rrule">0.33</td>
                                 <td styleCode="Rrule">2.0</td>
                                 <td styleCode="Rrule">0.039</td>
                                 <td styleCode="Rrule">2.4<footnoteRef IDREF="ft1"/>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">%CV</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">25%</td>
                                 <td styleCode="Rrule">(50%)</td>
                                 <td styleCode="Rrule">(36%)</td>
                                 <td styleCode="Rrule">(19%)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">22</td>
                                 <td styleCode="Rrule">0.55</td>
                                 <td styleCode="Rrule">2.1</td>
                                 <td styleCode="Rrule">0.14</td>
                                 <td styleCode="Rrule">5.8<footnoteRef IDREF="ft1"/>
                                 </td>
                                 <td styleCode="Rrule">84.5</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">%CV</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">(18%)</td>
                                 <td styleCode="Rrule">(52%)</td>
                                 <td styleCode="Rrule">(26%)</td>
                                 <td styleCode="Rrule">(25%)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">600 mg tablet/day (leukocytes)</td>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">22</td>
                                 <td styleCode="Rrule">252</td>
                                 <td styleCode="Rrule">10.9</td>
                                 <td styleCode="Rrule">146</td>
                                 <td styleCode="Rrule">4,763<footnoteRef IDREF="ft1"/>
                                 </td>
                                 <td styleCode="Rrule">82.8</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">%CV</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">(49%)</td>
                                 <td styleCode="Rrule">(28%)</td>
                                 <td styleCode="Rrule">(33%)</td>
                                 <td styleCode="Rrule">(42%)</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>With a regimen of 500 mg on Day 1 and 250 mg/day on Days 2 to 5, C<sub>min</sub> and C<sub>max</sub> remained essentially unchanged from Day 2 through Day 5 of therapy. However, without a loading dose, azithromycin C<sub>min</sub> levels required 5 to 7 days to reach steady state.</paragraph>
                        <paragraph>In asymptomatic HIV-positive adult subjects receiving 600 mg azithromycin tablets once daily for 22 days, steady state azithromycin serum levels were achieved by Day 15 of dosing.</paragraph>
                        <paragraph>The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="f1f0c774-51df-479e-9dbf-88170357039c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Absorption</content>
                              </paragraph>
                              <paragraph>The 1 gram single<content styleCode="bold">-</content>dose packet is bioequivalent to four 250 mg azithromycin capsule.</paragraph>
                              <paragraph>When the oral suspension of azithromycin was administered with food, the C<sub>max</sub> increased by 46% and the AUC by 14%.</paragraph>
                              <paragraph>The absolute bioavailability of two 600 mg tablets was 34% (CV = 56%). Administration of two 600 mg tablets with food increased C<sub>max</sub> by 31% (CV = 43%) while the extent of absorption (AUC) was unchanged (mean ratio of AUCs = 1.00; CV = 55%).</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="180392d7-e869-4184-8f2c-48595f398669"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Distribution</content>
                              </paragraph>
                              <paragraph>The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL.</paragraph>
                              <paragraph>The antibacterial activity of azithromycin is pH related and appears to be reduced with decreasing pH. However, the extensive distribution of drug to tissues may be relevant to clinical activity.</paragraph>
                              <paragraph>Azithromycin has been shown to penetrate into tissues in humans, including skin, lung, tonsil, and cervix. Extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder). As there are no data from adequate and well-controlled studies of azithromycin treatment of infections in these additional body sites, the clinical importance of these tissue concentration data is unknown.</paragraph>
                              <paragraph>Azithromycin concentrates in phagocytes and fibroblasts as demonstrated by <content styleCode="italics">in vitro</content> incubation techniques. Using such methodology, the ratio of intracellular to extracellular concentration was &gt; 30 after one hr of incubation. <content styleCode="italics">In vivo</content> studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.</paragraph>
                              <paragraph>Following oral administration of a single 1,200 mg dose (two 600 mg tablets), the mean maximum concentration in peripheral leukocytes was 140 mcg/mL. Concentration remained above 32 mcg/mL, for approximately 60 hr. The mean half-lives for 6 males and 6 females were 34 hr and 57 hr, respectively. Leukocyte-to-plasma C<sub>max</sub> ratios for males and females were 258 ( 77%) and 175 ( 60%), respectively, and the AUC ratios were 804 ( 31%) and 541 ( 28%), respectively. The clinical relevance of these findings is unknown.</paragraph>
                              <paragraph>Following oral administration of multiple daily doses of 600 mg (1 tablet/day) to asymptomatic HIV-positive adults, mean maximum concentration in peripheral leukocytes was 252 mcg/mL ( 49%). Trough concentrations in peripheral leukocytes at steady-state averaged 146 mcg/mL ( 33%). The mean leukocyte-to-serum C<sub>max</sub> ratio was 456 ( 38%) and the mean leukocyte to serum AUC ratio was 816 ( 31%). The clinical relevance of these findings is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="45f12db4-bd77-45d7-82da-fb118031aa40"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Metabolism</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content> and <content styleCode="italics">in vivo</content> studies to assess the metabolism of azithromycin have not been performed.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ccc8714d-f929-4639-8558-715f3ddd9635"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Elimination</content>
                              </paragraph>
                              <paragraph>Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr. Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in urine.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="25e1a1c9-4881-41be-ad7c-947abaf05437"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Specific Populations </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                           <component>
                              <section>
                                 <id root="209d5c21-c03d-418e-8bc9-084a914647b1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Azithromycin pharmacokinetics was investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1.0 g dose of azithromycin (4  250 mg capsules), the mean C<sub>max</sub> and AUC<sub>0-120</sub> increased by 5.1% and 4.2%, respectively, in subjects with GFR 10 mL/min to 80 mL/min compared to subjects with normal renal function (GFR &gt; 80 mL/min). The mean C<sub>max</sub> and AUC<sub>0-120</sub> increased 61% and 35%, respectively, in subjects with end-stage renal disease (GFR &lt; 10 mL/min) compared to subjects with normal renal function (GFR &gt; 80 mL/min<content styleCode="italics">).</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20211109"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="538b23ae-da77-42fd-9a2a-7cbab39cf5e7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established.</paragraph>
                                 </text>
                                 <effectiveTime value="20211109"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="261cc3a0-4547-4d49-8511-12bca2bd6b81"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Male and Female Patients</content>
                                    </paragraph>
                                    <paragraph>There are no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment is recommended on the basis of gender.</paragraph>
                                 </text>
                                 <effectiveTime value="20211109"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="6c82bff9-f939-499d-908f-5caa4e146b1c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>Pharmacokinetic parameters in older volunteers (65 to 85 years old) were similar to those in younger volunteers (18 to 40 years old) for the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen. <content styleCode="italics">[see <linkHtml href="#S8.5">Geriatric Use (8.5)</linkHtml>]</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20211109"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="00125b0f-da4c-46a2-a641-70b06a1a89b8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Pediatric Patients </content>
                                    </paragraph>
                                    <paragraph>For information regarding the pharmacokinetics of azithromycin for oral suspension in pediatric patients, see the prescribing information for azithromycin for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles.</paragraph>
                                 </text>
                                 <effectiveTime value="20211109"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b40a6807-64b7-4672-bdad-b4aa7d9d2bbc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered. The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1 and the effects of other drugs on the pharmacokinetics of azithromycin are shown in Table 2.</paragraph>
                              <paragraph>Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in Table 1. No dosage adjustment of drugs listed in Table 1 is recommended when co-administered with azithromycin.</paragraph>
                              <paragraph>Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C<sub>max</sub> and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in Table 2. <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>
                              </paragraph>
                              <table width="90%" ID="Table1">
                                 <caption>Table 1. Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin</caption>
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="20%"/>
                                 <col align="center" valign="middle" width="27%"/>
                                 <col align="center" valign="middle" width="8%"/>
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="15%"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Co-administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">Dose of Co-administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">Dose of Azithromycin</th>
                                       <th styleCode="Rrule" rowspan="2">n</th>
                                       <th styleCode="Rrule" colspan="2">Ratio (with/without azithromycin) of Co-administered Drug Pharmacokinetic Parameters <br/>(90% CI);<br/>No Effect = 1.00</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule">Mean C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">Mean AUC</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Atorvastatin</td>
                                       <td styleCode="Rrule">10 mg/day for 8 days</td>
                                       <td styleCode="Rrule">500 mg/day orally on days 6 to 8</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">0.83<br/>(0.63 to 1.08)</td>
                                       <td styleCode="Rrule">1.01<br/>(0.81 to 1.25)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Carbamazepine</td>
                                       <td styleCode="Rrule">200 mg/day for 2 days, then 200 mg twice a day for 18 days</td>
                                       <td styleCode="Rrule">500 mg/day orally for days 16 to 18</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">0.97<br/>(0.88 to 1.06)</td>
                                       <td styleCode="Rrule">0.96<br/>(0.88 to 1.06)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cetirizine</td>
                                       <td styleCode="Rrule">20 mg/day for 11 days</td>
                                       <td styleCode="Rrule">500 mg orally on day 7, then 250 mg/day on days 8 to 11</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">1.03<br/>(0.93 to 1.14)</td>
                                       <td styleCode="Rrule">1.02<br/>(0.92 to 1.13)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Didanosine</td>
                                       <td styleCode="Rrule">200 mg orally twice a day for 21 days</td>
                                       <td styleCode="Rrule">1,200 mg/day orally on days 8 to 21</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">1.44<br/>(0.85 to 2.43)</td>
                                       <td styleCode="Rrule">1.14<br/>(0.83 to 1.57)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Efavirenz</td>
                                       <td styleCode="Rrule">400 mg/day for 7 days</td>
                                       <td styleCode="Rrule">600 mg orally on day 7</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">1.04<footnote ID="t1f1">-90% Confidence interval not reported</footnote>
                                       </td>
                                       <td styleCode="Rrule">0.95<footnoteRef IDREF="t1f1"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fluconazole</td>
                                       <td styleCode="Rrule">200 mg orally single dose</td>
                                       <td styleCode="Rrule">1,200 mg orally single dose</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">1.04<br/>(0.98 to 1.11)</td>
                                       <td styleCode="Rrule">1.01<br/>(0.97 to 1.05)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Indinavir</td>
                                       <td styleCode="Rrule">800 mg three times a day for 5 days</td>
                                       <td styleCode="Rrule">1,200 mg orally on day 5</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">0.96<br/>(0.86 to 1.08)</td>
                                       <td styleCode="Rrule">0.90<br/>(0.81 to 1.00)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Midazolam</td>
                                       <td styleCode="Rrule">15 mg orally on day 3</td>
                                       <td styleCode="Rrule">500 mg/day orally for 3 days</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.27<br/>(0.89 to 1.81)</td>
                                       <td styleCode="Rrule">1.26<br/>(1.01 to 1.56)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nelfinavir</td>
                                       <td styleCode="Rrule">750 mg three times a day for 11 days</td>
                                       <td styleCode="Rrule">1,200 mg orally on day 9</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0.90<br/>(0.81 to 1.01)</td>
                                       <td styleCode="Rrule">0.85<br/>(0.78 to 0.93)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sildenafil</td>
                                       <td styleCode="Rrule">100 mg on days 1 and 4</td>
                                       <td styleCode="Rrule">500 mg/day orally for 3 days</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.16<br/>(0.86 to 1.57)</td>
                                       <td styleCode="Rrule">0.92<br/>(0.75 to 1.12)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Theophylline</td>
                                       <td styleCode="Rrule">4 mg/kg IV on days 1, 11, 25</td>
                                       <td styleCode="Rrule">500 mg orally on day 7, 250 mg/day on days 8 to 11</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.19<br/>(1.02 to 1.40)</td>
                                       <td styleCode="Rrule">1.02<br/>(0.86 to 1.22)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Theophylline</td>
                                       <td styleCode="Rrule">300 mg orally BID  15 days</td>
                                       <td styleCode="Rrule">500 mg orally on day 6, then 250 mg/day on days 7 to 10</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">1.09<br/>(0.92 to 1.29)</td>
                                       <td styleCode="Rrule">1.08<br/>(0.89 to 1.31)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Triazolam</td>
                                       <td styleCode="Rrule">0.125 mg on day 2</td>
                                       <td styleCode="Rrule">500 mg orally on day 1, then 250 mg/day on day 2</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.06<footnoteRef IDREF="t1f1"/>
                                       </td>
                                       <td styleCode="Rrule">1.02<footnoteRef IDREF="t1f1"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Trimethoprim/Sulfamethoxazole</td>
                                       <td styleCode="Rrule">160 mg/800 mg/day orally for 7 days</td>
                                       <td styleCode="Rrule">1,200 mg orally on day 7</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">0.85<br/>(0.75 to 0.97)/<br/>0.90<br/>(0.78 to 1.03)</td>
                                       <td styleCode="Rrule">0.87<br/>(0.80 to 0.95)/<br/>0.96<br/>(0.88 to 1.03)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Zidovudine</td>
                                       <td styleCode="Rrule">500 mg/day orally for 21 days</td>
                                       <td styleCode="Rrule">600 mg/day orally for 14 days</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">1.12<br/>(0.42 to 3.02)</td>
                                       <td styleCode="Rrule">0.94<br/>(0.52 to 1.70)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Zidovudine</td>
                                       <td styleCode="Rrule">500 mg/day orally for 21 days</td>
                                       <td styleCode="Rrule">1,200 mg/day orally for 14 days</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">1.31<br/>(0.43 to 3.97)</td>
                                       <td styleCode="Rrule">1.30<br/>(0.69 to 2.43)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="90%">
                                 <caption>Table 2. Drug Interactions: Pharmacokinetic Parameters for Azithromycin in the Presence of Co-administered Drugs. [see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</caption>
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="20%"/>
                                 <col align="center" valign="middle" width="27%"/>
                                 <col align="center" valign="middle" width="8%"/>
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="15%"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Co-administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">Dose of Co-administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">Dose of Azithromycin</th>
                                       <th styleCode="Rrule" rowspan="2">n</th>
                                       <th styleCode="Rrule" colspan="2">Ratio (with/without co-administered drug) of Azithromycin Pharmacokinetic Parameters <br/>(90% CI); No Effect = 1.00</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule">Mean C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">Mean AUC</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Efavirenz</td>
                                       <td styleCode="Rrule">400 mg/day for 7 days</td>
                                       <td styleCode="Rrule">600 mg orally on day 7</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">1.22 (1.04 to 1.42)</td>
                                       <td styleCode="Rrule">0.92<footnote>-90% Confidence interval not reported</footnote>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fluconazole</td>
                                       <td styleCode="Rrule">200 mg orally single dose</td>
                                       <td styleCode="Rrule">1,200 mg orally single dose</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">0.82 (0.66 to 1.02)</td>
                                       <td styleCode="Rrule">1.07 (0.94 to 1.22)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Nelfinavir</td>
                                       <td styleCode="Rrule">750 mg three times a day for 11 days</td>
                                       <td styleCode="Rrule">1,200 mg orally on day 9</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">2.36 (1.77 to 3.15)</td>
                                       <td styleCode="Rrule">2.12 (1.80 to 2.50)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="b35594c8-cc13-4398-861d-4c9873bddb9b"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="313c7afd-69cd-4aa6-8953-7adf6ee5dde0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a0492899-dad9-4687-a1e7-eac5a02743d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Resistance</content>
                              </paragraph>
                              <paragraph>The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation. Ribosomal modifications can determine cross resistance to other macrolides, lincosamides, and streptogramin B (MLSB phenotype). The mechanism of acquired mutational resistance in isolates of <content styleCode="italics">Mycobacterium avium</content> complex (i.e., 23S rRNA genemutation) is the same for both clarithromycin and azithromycin.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8d265dd6-9e02-49bb-92fe-af3c8309c0fd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Antimicrobial Activity</content>
                              </paragraph>
                              <paragraph>Azithromycin has been shown to be active against the following microorganisms, both <content styleCode="italics">in vitro</content> and in clinical infections. <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Mycobacteria</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="italics">Mycobacterium avium</content> complex (MAC) consisting of:</item>
                                 <item>
                                    <caption></caption><content styleCode="italics">Mycobacterium avium</content>
                                 </item>
                                 <item>
                                    <caption></caption><content styleCode="italics">Mycobacterium intracellulare</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Other Microorganisms</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="italics">Chlamydia trachomatis</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b4882612-abf9-4094-8ac8-088cacef159a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Susceptibility Testing </content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for azithromycin tablets, please see: https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="5d26c837-7620-4268-8f42-23352e32718a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20211109"/>
               <component>
                  <section ID="S13.1">
                     <id root="911c73d3-4df3-40ad-9ec9-8073b589549c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. In fertility studies conducted in male and female rats, oral administration of azithromycin for 64 to 66 days (males) or 15 days (females) prior to and during cohabitation resulted in decreased pregnancy rate at 20 mg/kg/day and 30 mg/kg/day when both males and females were treated with azithromycin. This minimal effect on pregnancy rate (approximately 12% reduction compared to concurrent controls) did not become more pronounced when the dose was increased from 20 mg/kg/day to 30 mg/kg/day (approximately 0.3 to 0.5 times the adult human daily dose of 600 mg based on body surface area) and it was not observed when only one animal in the mated pair was treated. There were no effects on any other reproductive parameters, and there were no effects on fertility at 10 mg/kg/day. The relevance of these findings to patients being treated with azithromycin at the doses and durations recommended in the prescribing information is uncertain.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="86389fff-1573-423b-88d7-62a0a41778be"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology</title>
                     <text>
                        <paragraph>Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) in dogs and rats treated with azithromycin at doses which, expressed on the basis of body surface area, are similar to or less than the highest recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (50 mg/kg/day dose) at the observed maximal plasma concentration of 1.3 mcg/mL (1.6 times the observed C<sub>max</sub> of 0.821 mcg/mL at the adult dose of 2 g). Similarly, it has been shown in the dog (10 mg/kg/day dose) at the observed maximal serum concentration of 1 mcg/mL (1.2 times the observed C<sub>max</sub> of 0.821 mcg/mL at the adult dose of 2 g).</paragraph>
                        <paragraph>Phospholipidosis was also observed in neonatal rats dosed for 18 days at 30 mg/kg/day, which is less than the pediatric dose of 60 mg/kg based on the surface area. It was not observed in neonatal rats treated for 10 days at 40 mg/kg/day with mean maximal serum concentrations of 1.86 mcg/mL, approximately 1.5 times the C<sub>max</sub> of 1.27 mcg/mL at the pediatric dose. Phospholipidosis has been observed in neonatal dogs (10 mg/kg/day) at maximum mean whole blood concentrations of 3.54 mcg/mL, approximately 3 times the pediatric dose C<sub>max</sub>.</paragraph>
                        <paragraph>The significance of the finding for animals and for humans is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="65e94878-a613-4654-a9a3-d44bd4273d02"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20211109"/>
               <component>
                  <section ID="S14.1">
                     <id root="8535e817-3d48-471f-99cc-34d17f499ece"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Clinical Studies in Patients with Advanced HIV Infection for the Prevention and Treatment of Disease Due to Disseminated <content styleCode="italics">Mycobacterium avium</content> Complex (MAC)</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                     <component>
                        <section>
                           <id root="572a8b91-4252-4566-840e-19376b63866c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Prevention of Disseminated MAC Disease</content>
                              </paragraph>
                              <paragraph>Two randomized, double-blind clinical trials were performed in patients with CD4 counts &lt; 100 cells/mcL. The first trial (Study 155) compared azithromycin (1,200 mg once weekly) to placebo and enrolled 182 patients with a mean CD4 count of 35 cells/mcL. The second trial (Study 174) randomized 723 patients to either azithromycin (1,200 mg once weekly), rifabutin (300 mg daily), or the combination of both. The mean CD4 count was 51 cells/mcL. The primary endpoint in these trials was disseminated MAC disease. Other endpoints included the incidence of clinically significant MAC disease and discontinuations from therapy for drug-related side effects.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="dba7744b-e709-471f-9fa0-a0efe5d08873"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">MAC bacteremia </content>
                              </paragraph>
                              <paragraph>In Study 155, 85 patients randomized to receive azithromycin and 89 patients randomized to receive placebo met the entrance criteria. Cumulative incidences at 6, 12, and 18 months of the possible outcomes are in the following table:</paragraph>
                              <table width="90%">
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="24%"/>
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="23%"/>
                                 <col align="center" valign="middle" width="23%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Cumulative Incidence Rate, %: Placebo (n = 89)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Month</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC Free and Alive</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Adverse Experience</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Lost to Follow-up</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">6</td>
                                       <td styleCode="Rrule">69.7</td>
                                       <td styleCode="Rrule">13.5</td>
                                       <td styleCode="Rrule">6.7</td>
                                       <td styleCode="Rrule">10.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">12</td>
                                       <td styleCode="Rrule">47.2</td>
                                       <td styleCode="Rrule">19.1</td>
                                       <td styleCode="Rrule">15.7</td>
                                       <td styleCode="Rrule">18.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">18</td>
                                       <td styleCode="Rrule">37.1</td>
                                       <td styleCode="Rrule">22.5</td>
                                       <td styleCode="Rrule">18.0</td>
                                       <td styleCode="Rrule">22.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Cumulative Incidence Rate, %: Azithromycin (n = 85)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Month</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC Free and Alive</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Adverse Experience</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Lost to Follow-up</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">6</td>
                                       <td styleCode="Rrule">84.7</td>
                                       <td styleCode="Rrule">3.5</td>
                                       <td styleCode="Rrule">9.4</td>
                                       <td styleCode="Rrule">2.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">12</td>
                                       <td styleCode="Rrule">63.5</td>
                                       <td styleCode="Rrule">8.2</td>
                                       <td styleCode="Rrule">16.5</td>
                                       <td styleCode="Rrule">11.8</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">18</td>
                                       <td styleCode="Rrule">44.7</td>
                                       <td styleCode="Rrule">11.8</td>
                                       <td styleCode="Rrule">25.9</td>
                                       <td styleCode="Rrule">17.6</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The difference in the one<content styleCode="bold">-</content>year cumulative incidence rates of disseminated MAC disease (placebo  azithromycin) is 10.9%. This difference is statistically significant (p = 0.037) with a 95% confidence interval for this difference of 0.8%, 20.9%. The comparable number of patients experiencing adverse events and the fewer number of patients lost to follow-up on azithromycin should be taken into account when interpreting the significance of this difference.</paragraph>
                              <paragraph>In Study 174, 223 patients randomized to receive rifabutin, 223 patients randomized to receive azithromycin, and 218 patients randomized to receive both rifabutin and azithromycin met the entrance criteria. Cumulative incidences at 6, 12, and 18 months of the possible outcomes are recorded in the following table:</paragraph>
                              <table width="90%">
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="24%"/>
                                 <col align="center" valign="middle" width="15%"/>
                                 <col align="center" valign="middle" width="23%"/>
                                 <col align="center" valign="middle" width="23%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Cumulative Incidence Rate, %: Rifabutin (n = 223)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Month</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC Free and Alive</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Adverse Experience</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Lost to Follow-up</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">6</td>
                                       <td styleCode="Rrule">83.4</td>
                                       <td styleCode="Rrule">7.2</td>
                                       <td styleCode="Rrule">8.1</td>
                                       <td styleCode="Rrule">1.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">12</td>
                                       <td styleCode="Rrule">60.1</td>
                                       <td styleCode="Rrule">15.2</td>
                                       <td styleCode="Rrule">16.1</td>
                                       <td styleCode="Rrule">8.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">18</td>
                                       <td styleCode="Rrule">40.8</td>
                                       <td styleCode="Rrule">21.5</td>
                                       <td styleCode="Rrule">24.2</td>
                                       <td styleCode="Rrule">13.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Cumulative Incidence Rate, %: Azithromycin (n = 223)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Month</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC Free and Alive</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Adverse Experience</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Lost to Follow-up</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">6</td>
                                       <td styleCode="Rrule">85.2</td>
                                       <td styleCode="Rrule">3.6</td>
                                       <td styleCode="Rrule">5.8</td>
                                       <td styleCode="Rrule">5.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">12</td>
                                       <td styleCode="Rrule">65.5</td>
                                       <td styleCode="Rrule">7.6</td>
                                       <td styleCode="Rrule">16.1</td>
                                       <td styleCode="Rrule">10.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">18</td>
                                       <td styleCode="Rrule">45.3</td>
                                       <td styleCode="Rrule">12.1</td>
                                       <td styleCode="Rrule">23.8</td>
                                       <td styleCode="Rrule">18.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Cumulative Incidence Rate, %: Azithromycin/Rifabutin Combination (n = 218)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Month</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC Free and Alive</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">MAC</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Adverse Experience</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Lost to Follow-up</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">6</td>
                                       <td styleCode="Rrule">89.4</td>
                                       <td styleCode="Rrule">1.8</td>
                                       <td styleCode="Rrule">5.5</td>
                                       <td styleCode="Rrule">3.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">12</td>
                                       <td styleCode="Rrule">71.6</td>
                                       <td styleCode="Rrule">2.8</td>
                                       <td styleCode="Rrule">15.1</td>
                                       <td styleCode="Rrule">10.6</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">18</td>
                                       <td styleCode="Rrule">49.1</td>
                                       <td styleCode="Rrule">6.4</td>
                                       <td styleCode="Rrule">29.4</td>
                                       <td styleCode="Rrule">15.1</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Comparing the cumulative one<content styleCode="bold">-</content>year incidence rates, azithromycin monotherapy is at least as effective as rifabutin monotherapy. The difference (rifabutin  azithromycin) in the one<content styleCode="bold">-</content>year rates (7.6%) is statistically significant (p = 0.022) with an adjusted 95% confidence interval (0.9%, 14.3%). Additionally, azithromycin/rifabutin combination therapy is more effective than rifabutin alone. The difference (rifabutin  azithromycin/rifabutin) in the cumulative one<content styleCode="bold">-</content>year incidence rates (12.5%) is statistically significant (p &lt; 0.001) with an adjusted 95% confidence interval of 6.6%, 18.4%. The comparable number of patients experiencing adverse events and the fewer number of patients lost to follow-up on rifabutin should be taken into account when interpreting the significance of this difference. </paragraph>
                              <paragraph>In Study 174, sensitivity testing<sup>1</sup> was performed on all available MAC isolates from subjects randomized to either azithromycin, rifabutin, or the combination. The distribution of MIC values for azithromycin from susceptibility testing of the breakthrough isolates was similar between trial arms. As the efficacy of azithromycin in the treatment of disseminated MAC has not been established, the clinical relevance of these <content styleCode="italics">in vitro</content> MICs as an indicator of susceptibility or resistance is not known.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7a3dc7c0-3470-4465-be88-5857ed1a38a0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Clinically Significant Disseminated MAC Disease</content>
                              </paragraph>
                              <paragraph>In association with the decreased incidence of bacteremia, patients in the groups randomized to either azithromycin alone or azithromycin in combination with rifabutin showed reductions in the signs and symptoms of disseminated MAC disease, including fever or night sweats, weight loss, and anemia.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a47730a1-0266-4c87-88e5-3b858dbfa2ec"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Discontinuations from Therapy for Drug-Related Side Effects</content>
                              </paragraph>
                              <paragraph>In Study 155, discontinuations for drug-related toxicity occurred in 8.2% of subjects treated with azithromycin and 2.3% of those given placebo (p = 0.121). In Study 174, more subjects discontinued from the combination of azithromycin and rifabutin (22.7%) than from azithromycin alone (13.5%; p = 0.026) or rifabutin alone (15.9%; p = 0.209).</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c45c5a18-3011-4d2a-b8b8-548fa119a631"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Safety</content>
                              </paragraph>
                              <paragraph>As these patients with advanced HIV disease were taking multiple concomitant medications and experienced a variety of intercurrent illnesses, it was often difficult to attribute adverse reactions to study medication. Overall, the nature of adverse reactions seen on the weekly dosage regimen of azithromycin over a period of approximately one year in patients with advanced HIV disease were similar to that previously reported for shorter course therapies.</paragraph>
                              <table width="90%">
                                 <caption>INCIDENCE OF ONE OR MORE TREATMENT-RELATED<footnote>Includes those reactions considered possibly or probably related to study drug</footnote> ADVERSE REACTIONS<footnote>&gt; 2% adverse reaction rates for any group (except uveitis)</footnote> IN HIV INFECTED PATIENTS RECEIVING PROPHYLAXIS FOR DISSEMINATED MAC OVER APPROXIMATELY 1 YEAR</caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2">Study 155</th>
                                       <th styleCode="Rrule" colspan="3">Study 174</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Placebo</th>
                                       <th styleCode="Rrule">Azithromycin<br/> 1,200 mg weekly</th>
                                       <th styleCode="Rrule">Azithromycin<br/> 1,200 mg weekly</th>
                                       <th styleCode="Rrule">Rifabutin <br/>300 mg daily</th>
                                       <th styleCode="Rrule">Azithromycin + Rifabutin</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" valign="baseline">(N = 91)</th>
                                       <th styleCode="Rrule">(N = 89)</th>
                                       <th styleCode="Rrule">(N = 233)</th>
                                       <th styleCode="Rrule">(N = 236)</th>
                                       <th styleCode="Rrule" valign="bottom">(N = 224)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Mean Duration of Therapy (days)</td>
                                       <td styleCode="Rrule">303.8</td>
                                       <td styleCode="Rrule">402.9</td>
                                       <td styleCode="Rrule">315</td>
                                       <td styleCode="Rrule">296.1</td>
                                       <td styleCode="Rrule">344.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Discontinuation of Therapy</td>
                                       <td styleCode="Rrule">2.3</td>
                                       <td styleCode="Rrule">8.2</td>
                                       <td styleCode="Rrule">13.5</td>
                                       <td styleCode="Rrule">15.9</td>
                                       <td styleCode="Rrule">22.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Autonomic Nervous System</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Mouth Dry</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3.0</td>
                                       <td styleCode="Rrule">2.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Central Nervous System</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1.1</td>
                                       <td styleCode="Rrule">3.9</td>
                                       <td styleCode="Rrule">1.7</td>
                                       <td styleCode="Rrule">0.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3.0</td>
                                       <td styleCode="Rrule">5.5</td>
                                       <td styleCode="Rrule">4.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">15.4</td>
                                       <td styleCode="Rrule">52.8</td>
                                       <td styleCode="Rrule">50.2</td>
                                       <td styleCode="Rrule">19.1</td>
                                       <td styleCode="Rrule">50.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Loose Stools</td>
                                       <td styleCode="Rrule">6.6</td>
                                       <td styleCode="Rrule">19.1</td>
                                       <td styleCode="Rrule">12.9</td>
                                       <td styleCode="Rrule">3.0</td>
                                       <td styleCode="Rrule">9.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal Pain</td>
                                       <td styleCode="Rrule">6.6</td>
                                       <td styleCode="Rrule">27</td>
                                       <td styleCode="Rrule">32.2</td>
                                       <td styleCode="Rrule">12.3</td>
                                       <td styleCode="Rrule">31.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspepsia</td>
                                       <td styleCode="Rrule">1.1</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">4.7</td>
                                       <td styleCode="Rrule">1.7</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Flatulence</td>
                                       <td styleCode="Rrule">4.4</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">10.7</td>
                                       <td styleCode="Rrule">5.1</td>
                                       <td styleCode="Rrule">5.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">32.6</td>
                                       <td styleCode="Rrule">27.0</td>
                                       <td styleCode="Rrule">16.5</td>
                                       <td styleCode="Rrule">28.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">1.1</td>
                                       <td styleCode="Rrule">6.7</td>
                                       <td styleCode="Rrule">9.0</td>
                                       <td styleCode="Rrule">3.8</td>
                                       <td styleCode="Rrule">5.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">General</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fever</td>
                                       <td styleCode="Rrule">1.1</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2.1</td>
                                       <td styleCode="Rrule">4.2</td>
                                       <td styleCode="Rrule">4.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2.2</td>
                                       <td styleCode="Rrule">3.9</td>
                                       <td styleCode="Rrule">2.1</td>
                                       <td styleCode="Rrule">3.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Malaise</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1.1</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Musculoskeletal</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Arthralgia</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3.0</td>
                                       <td styleCode="Rrule">4.2</td>
                                       <td styleCode="Rrule">7.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Psychiatric</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anorexia</td>
                                       <td styleCode="Rrule">1.1</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2.1</td>
                                       <td styleCode="Rrule">2.1</td>
                                       <td styleCode="Rrule">3.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Skin &amp; Appendages</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pruritus</td>
                                       <td styleCode="Rrule">3.3</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3.9</td>
                                       <td styleCode="Rrule">3.4</td>
                                       <td styleCode="Rrule">7.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash</td>
                                       <td styleCode="Rrule">3.2</td>
                                       <td styleCode="Rrule">3.4</td>
                                       <td styleCode="Rrule">8.1</td>
                                       <td styleCode="Rrule">9.4</td>
                                       <td styleCode="Rrule">11.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Skin discoloration</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2.1</td>
                                       <td styleCode="Rrule">2.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Special Senses</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Tinnitus</td>
                                       <td styleCode="Rrule">4.4</td>
                                       <td styleCode="Rrule">3.4</td>
                                       <td styleCode="Rrule">0.9</td>
                                       <td styleCode="Rrule">1.3</td>
                                       <td styleCode="Rrule">0.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hearing Decreased</td>
                                       <td styleCode="Rrule">2.2</td>
                                       <td styleCode="Rrule">1.1</td>
                                       <td styleCode="Rrule">0.9</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Uveitis</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">1.3</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Taste Perversion</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1.3</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">1.3</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Adverse reactions related to the gastrointestinal tract were seen more frequently in patients receiving azithromycin than in those receiving placebo or rifabutin. In Study 174, 86% of diarrheal episodes were mild to moderate in nature with discontinuation of therapy for this reason occurring in only 9/233 (3.8%) of patients.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8627d8bc-eb0d-4f1e-a1e3-5bcf6d3f99c8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Changes in Laboratory Values</content>
                              </paragraph>
                              <paragraph>In these immunocompromised patients with advanced HIV infection, it was necessary to assess laboratory abnormalities developing on trial with additional criteria if baseline values were outside the relevant normal range.</paragraph>
                              <table width="75%">
                                 <caption>PROPHYLAXIS AGAINST DISSEMINATED MAC ABNORMAL LABORATORY VALUES<footnote>excludes subjects outside of the relevant normal range at baseline</footnote>
                                 </caption>
                                 <col align="left" valign="middle" width="16%"/>
                                 <col align="left" valign="middle" width="16%"/>
                                 <col align="center" valign="middle" width="7%"/>
                                 <col align="center" valign="middle" width="7%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" colspan="2"/>
                                       <th styleCode="Rrule" colspan="2">Placebo</th>
                                       <th styleCode="Rrule" colspan="2">Azithromycin<br/> 1,200 mg weekly</th>
                                       <th styleCode="Rrule" colspan="2">Rifabutin<br/> 300 mg daily</th>
                                       <th styleCode="Rrule" colspan="2">Azithromycin &amp; Rifabutin</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">Hemoglobin</td>
                                       <td styleCode="Rrule">&lt; 8 g/dL</td>
                                       <td align="right">1/51</td>
                                       <td styleCode="Rrule" align="left">2%</td>
                                       <td align="right">4/170</td>
                                       <td styleCode="Rrule" align="left">2%</td>
                                       <td align="right">4/114</td>
                                       <td styleCode="Rrule" align="left">4%</td>
                                       <td align="right">8/107</td>
                                       <td styleCode="Rrule" align="left">8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">Platelet Count</td>
                                       <td styleCode="Rrule">&lt; 50  10<sup>3</sup>/mm<sup>3</sup>
                                       </td>
                                       <td align="right">1/71</td>
                                       <td styleCode="Rrule" align="left">1%</td>
                                       <td align="right">4/260</td>
                                       <td styleCode="Rrule" align="left">2%</td>
                                       <td align="right">2/182</td>
                                       <td styleCode="Rrule" align="left">1%</td>
                                       <td align="right">6/181</td>
                                       <td styleCode="Rrule" align="left">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">WBC Count</td>
                                       <td styleCode="Rrule">&lt; 1  10<sup>3</sup>/mm<sup>3</sup>
                                       </td>
                                       <td align="right">0/8</td>
                                       <td styleCode="Rrule" align="left">0%</td>
                                       <td align="right">2/70</td>
                                       <td styleCode="Rrule" align="left">3%</td>
                                       <td align="right">2/47</td>
                                       <td styleCode="Rrule" align="left">4%</td>
                                       <td align="right">0/43</td>
                                       <td styleCode="Rrule" align="left">0%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">Neutrophils</td>
                                       <td styleCode="Rrule">&lt; 500/mm<sup>3</sup>
                                       </td>
                                       <td align="right">0/26</td>
                                       <td styleCode="Rrule" align="left">0%</td>
                                       <td align="right">4/106</td>
                                       <td styleCode="Rrule" align="left">4%</td>
                                       <td align="right">3/82</td>
                                       <td styleCode="Rrule" align="left">4%</td>
                                       <td align="right">2/78</td>
                                       <td styleCode="Rrule" align="left">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">SGOT</td>
                                       <td styleCode="Rrule">&gt; 5  ULN<footnote>Upper Limit of Normal</footnote>
                                       </td>
                                       <td align="right">1/41</td>
                                       <td styleCode="Rrule" align="left">2%</td>
                                       <td align="right">8/158</td>
                                       <td styleCode="Rrule" align="left">5%</td>
                                       <td align="right">3/121</td>
                                       <td styleCode="Rrule" align="left">3%</td>
                                       <td align="right">6/114</td>
                                       <td styleCode="Rrule" align="left">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">SGPT</td>
                                       <td styleCode="Rrule">&gt; 5  ULN</td>
                                       <td align="right">0/49</td>
                                       <td styleCode="Rrule" align="left">0%</td>
                                       <td align="right">8/166</td>
                                       <td styleCode="Rrule" align="left">5%</td>
                                       <td align="right">3/130</td>
                                       <td styleCode="Rrule" align="left">2%</td>
                                       <td align="right">5/117</td>
                                       <td styleCode="Rrule" align="left">4%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Alk Phos</td>
                                       <td styleCode="Rrule">&gt; 5  ULN</td>
                                       <td align="right">1/80</td>
                                       <td styleCode="Rrule" align="left">1%</td>
                                       <td align="right">4/247</td>
                                       <td styleCode="Rrule" align="left">2%</td>
                                       <td align="right">2/172</td>
                                       <td styleCode="Rrule" align="left">1%</td>
                                       <td align="right">3/164</td>
                                       <td styleCode="Rrule" align="left">2%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8a20de37-9604-44f0-b6f3-49e8159be894"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Treatment of Disseminated MAC Disease</content>
                              </paragraph>
                              <paragraph>One randomized, double<content styleCode="bold">-</content>blind clinical trial (Study 189) was performed in patients with disseminated MAC. In this trial, 246 HIV<content styleCode="bold">-</content>infected patients with disseminated MAC received either azithromycin 250 mg daily (N = 65), azithromycin 600 mg daily (N = 91), or clarithromycin 500 mg twice a day (N = 90), each administered with ethambutol 15 mg/kg daily, for 24 weeks. Blood cultures and clinical assessments were performed every 3 weeks through week 12 and monthly thereafter through week 24. After week 24, patients were switched to any open<content styleCode="bold">-</content>label therapy at the discretion of the investigator and followed every 3 months through the last follow<content styleCode="bold">-</content>up visit of the trial. Patients were followed from the baseline visit for a period of up to 3.7 years (median: 9 months). MAC isolates recovered during treatment or post-treatment were obtained whenever possible.</paragraph>
                              <paragraph>The primary endpoint was sterilization by week 24. Sterilization was based on data from the central laboratory, and was defined as two consecutive observed negative blood cultures for MAC, independent of missing culture data between the two negative observations. Analyses were performed on all randomized patients who had a positive baseline culture for MAC.</paragraph>
                              <paragraph>The azithromycin 250 mg arm was discontinued after an interim analysis at 12 weeks showed a significantly lower clearance of bacteremia compared to clarithromycin 500 mg twice a day. Efficacy results for the azithromycin 600 mg daily and clarithromycin 500 mg twice a day treatment regimens are described in the following table:</paragraph>
                              <table width="75%">
                                 <caption>RESPONSE TO THERAPY OF PATIENTS TAKING ETHAMBUTOL AND EITHER AZITHROMYCIN 600 MG DAILY OR CLARITHROMYCIN 500 MG TWICE A DAY</caption>
                                 <col width="35%" align="left" valign="middle"/>
                                 <col width="20%" align="left" valign="middle"/>
                                 <col width="25%" align="left" valign="middle"/>
                                 <col width="20%" align="left" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Azithromycin<br/> 600 mg daily</th>
                                       <th styleCode="Rrule">Clarithromycin <br/>500 mg twice a day</th>
                                       <th styleCode="Rrule" valign="middle">
                                          <footnote>[95% confidence interval] on difference in rates (azithromycin-clarithromycin)</footnote>95.1% CI on difference</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Patients with positive culture at baseline</td>
                                       <td styleCode="Rrule">68</td>
                                       <td styleCode="Rrule">57</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Week 24</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule" valign="middle">
                                       <td styleCode="Lrule Rrule">Two consecutive negative blood cultures<footnote>Primary endpoint</footnote>
                                       </td>
                                       <td styleCode="Rrule">31/68 (46%)</td>
                                       <td styleCode="Rrule">32/57 (56%)</td>
                                       <td styleCode="Rrule">[-28, 7]</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Mortality</td>
                                       <td styleCode="Rrule">16/68 (24%)</td>
                                       <td styleCode="Rrule">15/57 (26%)</td>
                                       <td styleCode="Rrule">[-18, 13]</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The primary endpoint, rate of sterilization of blood cultures (two consecutive negative cultures) at 24 weeks, was lower in the azithromycin 600 mg daily group than in the clarithromycin 500 mg twice a day group.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="530cd287-f0bf-44fb-8e77-bc643824c63c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Sterilization by Baseline Colony Count</content>
                              </paragraph>
                              <paragraph>Within both treatment groups, the sterilization rates at week 24 decreased as the range of MAC cfu/mL increased.</paragraph>
                              <table width="75%">
                                 <col width="29%" align="left" valign="middle"/>
                                 <col width="31%" align="left" valign="middle"/>
                                 <col width="40%" align="left" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Azithromycin 600 mg (N = 68)</th>
                                       <th styleCode="Rrule">Clarithromycin 500 mg twice a day (N = 57)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule">groups stratified by MAC colony counts at baseline</th>
                                       <th styleCode="Rrule">no. (%) subjects in stratified group sterile at week 24</th>
                                       <th styleCode="Rrule">no. (%) subjects in stratified group sterile at week 24</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"> 10 cfu/mL</td>
                                       <td styleCode="Rrule">10/15 (66.7%)</td>
                                       <td styleCode="Rrule">12/17 (70.6%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">11 cfu/mL to 100 cfu/mL</td>
                                       <td styleCode="Rrule">13/28 (46.4%)</td>
                                       <td styleCode="Rrule">13/19 (68.4%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">101 cfu/mL to 1,000 cfu/mL</td>
                                       <td styleCode="Rrule">7/19 (36.8%)</td>
                                       <td styleCode="Rrule">5/13 (38.5%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">1,001 cfu/mL to 10,000 cfu/mL</td>
                                       <td styleCode="Rrule">1/5 (20.0%)</td>
                                       <td styleCode="Rrule">1/5 (20%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">&gt; 10,000 cfu/mL</td>
                                       <td styleCode="Rrule">0/1 (0.0%)</td>
                                       <td styleCode="Rrule">1/3 (33.3%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c08a0f3f-22be-4404-b845-96b0a7026dd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Susceptibility Pattern of MAC Isolates</content>
                              </paragraph>
                              <paragraph>Susceptibility testing was performed on MAC isolates recovered at baseline, at the time of breakthrough on therapy or during post-therapy follow-up. The T100 radiometric broth method was employed to determine azithromycin and clarithromycin MIC values. Azithromycin MIC values ranged from &lt; 4 mcg/mL to &gt; 256 mcg/mL and clarithromycin MICs ranged from &lt; 1 mcg/mL to &gt; 32 mcg/mL. The individual MAC susceptibility results demonstrated that azithromycin MIC values could be 4 to 32<content styleCode="bold">-</content>fold higher than clarithromycin MIC values.</paragraph>
                              <paragraph>During treatment and post-treatment follow<content styleCode="bold">-</content>up for up to 3.7 years (median: 9 months) in Study 189, a total of 6/68 (9%) and 6/57 (11%) of the patients randomized to azithromycin 600 mg daily and clarithromycin 500 mg twice a day respectively, developed MAC blood culture isolates that had a sharp increase in MIC values. All twelve MAC isolates had azithromycin MICs    256 mcg/mL and clarithromycin MICs &gt; 32 mcg/mL. These high MIC values suggest development of drug resistance. However, at this time, specific breakpoints for separating susceptible and resistant MAC isolates have not been established for either macrolide.</paragraph>
                           </text>
                           <effectiveTime value="20211109"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="44b3651d-313a-4dc5-944e-8f525d4b913e"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered" styleCode="arabic">
                     <item>Griffith DE, Aksamit T, Brown-Elliot BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. <content styleCode="italics">Am J Respir Crit Care Med.</content> 2007; 175:367-416.</item>
                  </list>
               </text>
               <effectiveTime value="20211109"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="07e12863-8577-4153-8007-c78ef5141290"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Azithromycin Tablets USP, 600 mg (debossed "OE" on one side and "600" on the other side) are supplied as white, oval-shaped, film coated tablets containing azithromycin dihydrate equivalent to 600 mg azithromycin. These are packaged in bottles of 30 tablets:</paragraph>
                  <table width="65%" styleCode="Noautorules">
                     <col width="52%" align="left" valign="top"/>
                     <col width="48%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles of 30 tablets with child-resistant closure</td>
                           <td>NDC 51224-222-30</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20211109"/>
               <component>
                  <section>
                     <id root="eca029ff-c5a0-4e45-8924-d54c32deddbf"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Storage</content>
                        </paragraph>
                        <paragraph>Store at 20 to 25C (68 to 77F); excursions permitted from 15 to 30C (59 to 86F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph>Dispense in tight containers (USP).</paragraph>
                     </text>
                     <effectiveTime value="20211109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="da17b0ea-672b-46c8-8b44-9b7ac7557fa5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Azithromycin tablets may be taken with or without food. However, increased tolerability has been observed when tablets are taken with food.</paragraph>
                  <paragraph>Patients should also be cautioned not to take aluminum- and magnesium-containing antacids and azithromycin simultaneously.</paragraph>
                  <paragraph>The patient should be directed to discontinue azithromycin immediately and contact a physician if any signs of an allergic reaction occur.</paragraph>
                  <paragraph>Direct parents or caregivers to contact their physician if vomiting and irritability with feeding occurs in the infant.</paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs, including azithromycin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When azithromycin is prescribed to treat bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by azithromycin or other antibacterial drugs in the future.</paragraph>
                  <paragraph>Diarrhea is a common problem caused by antibacterial which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.</paragraph>
               </text>
               <effectiveTime value="20211109"/>
            </section>
         </component>
         <component>
            <section>
               <id root="449d4037-fa03-4e6f-b700-c80c84754f5e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">CSPC Ouyi Pharmaceutical Co., Ltd.</content>
                     <br/>Shijiazhuang, Hebei, China, 052160</paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">TAGI Pharma, Inc.</content>
                     <br/>South Beloit, IL 61080</paragraph>
               </text>
               <effectiveTime value="20211109"/>
            </section>
         </component>
         <component>
            <section>
               <id root="abe8cbc0-a1a7-458c-afe1-b45fe452a8ea"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 600 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 51224-222-30</paragraph>
                  <paragraph>Azithromycin<br/>Tablets, USP</paragraph>
                  <paragraph>600 mg</paragraph>
                  <paragraph>CSPC<sup></sup>
                  </paragraph>
                  <paragraph>tagi PHARMA<br/>That's A Good Idea.</paragraph>
                  <paragraph>30 Tablets<br/>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20211109"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 600 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="azithromycin-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>